- Policy
- Negotiating Erleada's price with the NHIS
- by Lee, Tak-Sun Jan 27, 2023 05:51am
- It has been confirmed that Erleada, Janssen Korea's prostate cancer treatment, is negotiating drug prices with the NHIS. This drug was conditionally passed at the deliberation of the HIRA Drug Benefit Evaluation Committee in December last year. According to industries on the 25th, it is negotiating Erleada's price with the NHIS. Erleada was p
- Policy
- The copyrights of Valcyte, Alvesco, & Bonviva changed
- by Lee, Tak-Sun Jan 27, 2023 05:50am
- As the domestic owners of major drugs such as Valcyte, Alvesco, and Bonviva changed, they were newly reflected in the salary list. All three items were previously copyrighted by the Korean branch of a global pharmaceutical company, but now domestic pharmaceutical companies are the owners. In the case of Valcyte 440mg, pharmaceutical companies
- Policy
- MFDS preannounces temporary narcotics designation of 2 drugs
- by Lee, Hye-Kyung Jan 26, 2023 06:05am
- On January 20th, The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) preannounced the designation of two drugs including ‘Etazene’ that is being misused or abused as a narcotics substitute in Korea and abroad. Etazene is a synthetic opioid that has a similar structure and effect to Etonitazene,
- Policy
- Penalties for rebate drugs can be replaced by fines
- by Lee, Jeong-Hwan Jan 20, 2023 06:07am
- A bill will be promoted to replace drug price cuts and suspension of salaries for illegal rebates on drugs with fines. It also includes a clause that further strengthens the penalty standard for effective illegal rebate disposal. The move aims to solve the problem of increasing drug costs for patients who have to continue taking drugs due t
- Policy
- Rinvoq PR 30 mg & Fexuclu 10 mg listed
- by Lee, Jeong-Hwan Jan 20, 2023 06:07am
- With the new listing of high-content products of Rinvoq PR, a severe atopic drug, the salary standard changes. The angina drug Procoralan is a standard treatment drug and an angiotensin II receptor blocker is added. Fexuclu, a gastroesophageal reflux disease drug, will have four new benefits listed, including a low content of 10 mg oral medic
- Policy
- Grace period for foreign API mfg site registrations ends
- by Lee, Hye-Kyung Jan 19, 2023 05:58am
- Starting on the 21st, the foreign manufacturing site for all pharmaceuticals (including APIs) imported to Korea from abroad must be registered in advance. The Ministry of Food and Drug Safety announced that the grace period that had been granted in consideration of the industry’s state of preparations in registering foreign manufacturing
- Policy
- Generic for Dukarb to be released next month
- by Lee, Tak-Sun Jan 18, 2023 06:04am
- Generic for Dukarb, a compound combined with Amlodipine in the new hypertension drug Kanarb developed by Boryung pharmaceutical, is expected to release in time for the expiration of the patent next month. Eight items from four companies approved last month will go to the market first, and they will be calculated at 53.55% of the initial price
- Policy
- MOHW-NECA issues notice on colorimetric assay
- by Kim, Jung-Ju Jan 18, 2023 06:04am
- The National Evidence-based healthcare Collaborating Agency (President: Kwang Hyub Han) announced the amendments to the notice on the new health technology, ‘colorimetric assay’ for anti-Xa apixaban testing, that had been deliberated as a safe and effective health technology at the 10th MOHW New Health Technology Assessment Committee mee
- Policy
- Dupxient deemed adequate for reimb in children with AD
- by Lee, Tak-Sun Jan 13, 2023 06:01am
- The atopic dermatitis treatment ‘Dupixent’ was deemed adequate for reimbursement in children and adolescents. Therefore, attention is now focused on whether Dupixent will become the first biological agent to be reimbursed for atopic dermatitis in children and adolescents. The Health Insurance Review and Assessment Service announced that
- Policy
- Lee Jong-sung, who pointed out Moon Care
- by Lee, Jeong-Hwan Jan 13, 2023 06:01am
- Lee Jong-sung, a member of the National Assembly's Health and Welfare Committee, pointed out that Moon Jae In Care's health insurance coverage rate has fallen and said he will take the lead in making policies for normalization. Rep. Lee Jong-sung posted this message on his social media on the 11th. Representative Lee criticized the failur
